Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00063076 · ClinicalTrials.gov registry record · Phase 2
Phase II Randomized Bilateral Comparison of Topical Targretin Gel 1% in Alopecia Areata
A Phase 2 study, sponsored by M.D. Anderson Cancer Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 46
- Enrollment target
NCT00063076: Completed Phase 2 study, sponsored by M.D. Anderson Cancer Center.
NCT00063076 is a Phase 2 study that has completed, run by M.D. Anderson Cancer Center. The registered enrollment target is 46 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (65% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00063076, a Phase 2 study, has completed, sponsored by M.D. Anderson Cancer Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 46 participants
- Enrollment target
Study Summary
The goal of this clinical research study is to find the most effective dose of Targretin® (bexarotene) Gel 1% that can be given to patients as a treatment for alopecia areata. The safety and tolerability of this drug will also be studied. Objectives: 1. Determine the safety and tolerability of Targretin® Gel 1% in the treatment of patients with alopecia areata. 2. Determine the efficacy of Targretin® Gel 1% in the treatment of patients with alopecia areata.
Primary Outcome
"Response" defined as hair growth at PGA grade 3 or 4, and "toxicity" as vesiculation grade 3 or ulceration at grade 4 using design of Thall, Simon and Estey (1995, 1996). To monitor response and toxicity, four possible elementary outcomes are: 1 = \[no toxicity, no response\], 2 = \[no toxicity, response\], 3 = \[toxicity, no response\] , 4 = \[toxicity, response\].
Interventions
- DRUG Targretin Gel 1%
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 46 participants |
| Start Date | 2003-05 |
| Est. Completion | 2007-05 |
| Phase | Phase 2 |
What the finished NCT00063076 record still lists
NCT00063076 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 46 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (65% lower).
The record links to 0 conditions, and to 1 intervention - of which Targretin Gel 1% is the first listed.
NCT00063076 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00063076 about?
NCT00063076 is a clinical study titled "Phase II Randomized Bilateral Comparison of Topical Targretin Gel 1% in Alopecia Areata". The goal of this clinical research study is to find the most effective dose of Targretin® (bexarotene) Gel 1% that can be given to patients as a treatment for alopecia areata. The safety and tolerability of this drug will also be studied. Objectives: 1. Determine the safety and tolerability of Tar...
What is the current status of trial NCT00063076?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 46 participants. The study started on 2003-05. Estimated completion is 2007-05.
What interventions are being tested in trial NCT00063076?
The interventions under investigation include: Targretin Gel 1% (DRUG).
Who is sponsoring clinical trial NCT00063076?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00063076's enrollment target sits among peer trials
46 1286th of 2000 higher than 705 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01890590 · 46 participants · NA
A Phase II Study of Cyberknife Radiosurgery for Renal Cell Carcinoma
- NCT03191149 · 46 participants · Phase 2
Testing Osimertinib as a Treatment for Lung Cancers With an EGFR Exon 20 Change
- NCT03510208 · 46 participants · Phase 1
Panitumumab-IRDye800 in Diagnosing Participants With Malignant Glioma Undergoing Surgery
- NCT04048278 · 46 participants · Early Phase 1
Lidocaine Infusion in Pancreatic Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia